Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies
NCT01548521
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
5
Enrollment
OTHER
Sponsor class
Conditions
Prader-Willi Syndrome
Interventions
DRUG:
Oxytocin
Sponsor
University Hospital, Toulouse